What is Dr Reddy's Laboratories Return-on-Tangible-Asset?
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Dr Reddy's Laboratories's annualizedNet Income for the quarter that ended in Mar. 2024 was $631 Mil. Dr Reddy's Laboratories's average total tangible assets for the quarter that ended in Mar. 2024 was $4,077 Mil. Therefore, Dr Reddy's Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 15.48%.
The historical rank and industry rank for Dr Reddy's Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
RDY'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 5.63 Med: 10.47 Max: 17.82
Current: 17.82
During the past 13 years, Dr Reddy's Laboratories's highest Return-on-Tangible-Asset was 17.82%. The lowest was 5.63%. And the median was 10.47%.
RDY's Return-on-Tangible-Asset is ranked better than 94.09% of 1083
companies
in the Drug Manufacturers industry
Industry Median: 1.83
vs RDY: 17.82
Dr Reddy's Laboratories Return-on-Tangible-Asset Historical Data
The historical data trend for Dr Reddy's Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Dr Reddy's Laboratories Return-on-Tangible-Asset Chart
Competitive Comparison of Dr Reddy's Laboratories's Return-on-Tangible-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dr Reddy's Laboratories's Return-on-Tangible-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Dr Reddy's Laboratories's Return-on-Tangible-Asset falls into.
Dr Reddy's Laboratories Return-on-Tangible-Asset Calculation
Dr Reddy's Laboratories's annualized Return-on-Tangible-Asset for the fiscal year that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2024) net income data.
Dr Reddy's Laboratories (NYSE:RDY) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Dr Reddy's Laboratories Return-on-Tangible-Asset Related Terms
Thank you for viewing the detailed overview of Dr Reddy's Laboratories's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Dr Reddy's Laboratories (Dr Reddy's Laboratories) Business Description
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
Dr Reddy's Laboratories (Dr Reddy's Laboratories) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RDY has been successfully added to your 